Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Hoffmann-La Roche, Janssen Research & Development, LLC
The Key Myasthenia Gravis Companies in the market include - Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others.
DelveInsight's 'Myasthenia Gravis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Some of the key facts of the Myasthenia Gravis Market Report:
Among the 7MM countries the Myasthenia Gravis market size was valued approximately USD 3,880 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In April 2025, Impressive findings from the Phase 3 clinical trial (NCT05737160) evaluating the safety and effectiveness of Telitacicept (also known as RC18; brand name: 泰爱®) in individuals with generalized myasthenia gravis (gMG) were presented during the Late-Breaking Science Session at the 2025 American Academy of Neurology (AAN) Annual Meeting.
In March 2025, Immunovant has opted not to seek regulatory approval for its myasthenia gravis (MG) therapy, batoclimab, even though the Phase III trial achieved its primary goal of reducing disease symptoms. Instead, the company plans to use the trial data to support the advancement of its alternative candidate, IMVT-1402. The Phase III randomized study (NCT05403541) evaluated the effects of weekly or bi-weekly batoclimab dosing in acetylcholine receptor antibody-positive (AChR+) patients, measuring improvements through the Myasthenia Gravis Activities of Daily Living (MG-ADL) score over 12 weeks.
In December 2024, Cartesian Therapeutics has shared updated efficacy and safety results from its Phase IIb trial evaluating Descartes-08, an mRNA cell therapy candidate for generalized myasthenia gravis (MG). The findings demonstrated durable responses at 12 months. This open-label, double-blind, placebo-controlled, crossover study (NCT06038474) enrolled 36 symptomatic patients who had previously undergone extensive treatment. Participants were divided evenly, with one group receiving a placebo and the other receiving Descartes-08. Both groups underwent six weekly outpatient infusions, administered without the need for prior chemotherapy-based preconditioning.
In October 2024, Cartesian Therapeutics, Inc. (NASDAQ: RNAC), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune disorders, announced plans to present findings from its Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis (MG). The data will be shared at the 2024 Myasthenia Gravis Foundation of America (MGFA) Scientific Session, held during the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting.
The combined myasthenia gravis market size in the European Union's four largest economies and the United Kingdom was approximately USD 950 million in 2023. This figure is expected to increase over the forecast period from 2024 to 2034.
In June 2024, Johnson & Johnson (NYSE: JNJ) has announced encouraging outcomes from the Phase 3 Vivacity-MG3 trial of nipocalimab in patients with generalized myasthenia gravis (gMG). The trial demonstrated that patients receiving nipocalimab alongside standard of care (SOC) showed significant improvement in the MG-ADL score over 24 weeks compared to those on placebo plus SOC, meeting the primary endpoint. These findings are part of eight abstracts Johnson & Johnson will present at the 2024 European Academy of Neurology (EAN) Congress. Additionally, the data will be included in regulatory submissions later this year.
In January 2024, Johnson & Johnson reported the headline findings from the critical Phase III VIVACITY trial of nipocalimab in adults with generalized myasthenia gravis (gMG). In this Phase III study, nipocalimab met its primary goal, demonstrating a statistically significant decrease in MG-ADL score from baseline during weeks 22 to 24 compared to placebo (PBO).
According to DelveInsight's evaluation in 2023, the seven major markets (7MM) had an estimated 297,000 diagnosed prevalent instances of myasthenia gravis, with an expected upward trajectory in these cases anticipated during the forecast period from 2024 to 2034.
In 2023, the United States had the largest number of diagnosed prevalent cases of myasthenia gravis among the seven major markets (7MM), totaling approximately 133,000 cases. It is projected that these figures will increase during the forecast period from 2024 to 2034.
In 2023, myasthenia gravis affected 48% of males and 52% of females across the seven major markets (7MM). In the United States, there were approximately 66,000 cases among males and around 67,000 cases among females in 2023. These gender-specific incidences are projected to increase during the forecast period from 2024 to 2034.
Emerging treatments for myasthenia gravis like Nipocalimab, Batoclimab, Descartes-08, ENSPRYNG (satralizumab), and others hold promise to substantially impact the market size of myasthenia gravis in a positive direction.
Key Myasthenia Gravis Companies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others
Key Myasthenia Gravis Therapies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others
The Myasthenia Gravis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Myasthenia Gravis pipeline products will significantly revolutionize the Myasthenia Gravis market dynamics.
Myasthenia Gravis Overview
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by weakness and fatigue of voluntary muscles. It occurs when the body's immune system mistakenly attacks and damages the communication between nerve cells and muscles, specifically at the neuromuscular junction.
Myasthenia Gravis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Myasthenia Gravis Epidemiology Segmentation:
The Myasthenia Gravis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Myasthenia Gravis
Prevalent Cases of Myasthenia Gravis by severity
Gender-specific Prevalence of Myasthenia Gravis
Diagnosed Cases of Episodic and Chronic Myasthenia Gravis
Download the report to understand which factors are driving Myasthenia Gravis epidemiology trends @ Myasthenia Gravis Epidemiology Forecast
Myasthenia Gravis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Myasthenia Gravis market or expected to get launched during the study period. The analysis covers Myasthenia Gravis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Myasthenia Gravis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Myasthenia Gravis Therapies and Key Companies
Myasthenia Gravis Market Strengths
The growing prevalence of myasthenia gravis (MG) and the geriatric population offers a stable market demand for treatments and therapies.
Myasthenia gravis treatments may qualify for orphan drug status, offering regulatory incentives, such as extended market exclusivity and tax benefits.
Myasthenia Gravis Market Opportunities
Potential for developing new, more effective therapies, such as gene therapy or targeted biologics, could address unmet medical needs.
Improved diagnostic techniques using clear biomarkers and an increase in awareness will likely lead to a diagnosis of more patients, expanding the market.
Scope of the Myasthenia Gravis Market Report
Study Period: 2020-2034
Coverage: 7MM Countries
Key Myasthenia Gravis Companies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others
Key Myasthenia Gravis Therapies: Hoffmann-La Roche, Janssen Research & Development, LLC, Immunovant Sciences GmbH, Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Argenx-Halozyme Therapeutics, Horizon Therapeutics, DAS Therapeutics, Chugai Pharmaceutical, Inc., Alexion, Regeneron Pharmaceuticals, Ra Pharmaceuticals, Inc., and others
Myasthenia Gravis Therapeutic Assessment: Myasthenia Gravis current marketed and Myasthenia Gravis emerging therapies
Myasthenia Gravis Market Dynamics: Myasthenia Gravis market drivers and Myasthenia Gravis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Myasthenia Gravis Unmet Needs, KOL's views, Analyst's views, Myasthenia Gravis Market Access and Reimbursement
Table of Contents
1. Myasthenia Gravis Market Report Introduction
2. Executive Summary for Myasthenia Gravis
3. SWOT analysis of Myasthenia Gravis
4. Myasthenia Gravis Patient Share (%) Overview at a Glance
5. Myasthenia Gravis Market Overview at a Glance
6. Myasthenia Gravis Disease Background and Overview
7. Myasthenia Gravis Epidemiology and Patient Population
8. Country-Specific Patient Population of Myasthenia Gravis
9. Myasthenia Gravis Current Treatment and Medical Practices
10. Myasthenia Gravis Unmet Needs
11. Myasthenia Gravis Emerging Therapies
12. Myasthenia Gravis Market Outlook
13. Country-Wise Myasthenia Gravis Market Analysis (2020-2034)
14. Myasthenia Gravis Market Access and Reimbursement of Therapies
15. Myasthenia Gravis Market Drivers
16. Myasthenia Gravis Market Barriers
17. Myasthenia Gravis Appendix
18. Myasthenia Gravis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
18 minutes ago
- CTV News
B.C. nurse suspended 12 months for sexual relationship with client
A B.C. nurse's registration has been suspended for 12 months as discipline for a sexual relationship the worker had with a client, according to the regulatory body. The B.C. College of Nurses and Midwives described the relationship, which happened between July and September of 2023, as 'personal and sexual.' The nurse, who is not named in the consent agreement reached with the college earlier this week due to privacy regulations, 'documented that at the time of the conduct, they suffered from a health condition that was a factor in their conduct,' reads an online summary. 'Intimate' relationships between nurses and clients are prohibited, even if they are consensual, the college said, adding that a breach of professional boundaries can harm the patient. 'The nurse-client relationship is the foundation of nursing practice across all populations and cultures and in all practice settings. It is therapeutic and focuses on the needs of the client. It is based on trust, respect and professional intimacy, and it requires the appropriate use of authority,' the summary reads. According to the college, the nurse agreed to have their registration suspended for 12 months and a six-month ban on working in community nursing. If they return to the job, the nurse will be required to be 'followed by' a counsellor for a year. 'The inquiry committee is satisfied that the terms will address the professional and practice concerns that arose and will protect the public,' the BCCNM wrote.
CTV News
5 hours ago
- CTV News
Japan launches a climate change monitoring satellite on mainstay H2A rocket's last flight
TOKYO — Japan on Sunday launched a satellite to monitor greenhouse gas emissions using its mainstay H-2A rocket, which made its final flight before it is replaced by a new flagship designed to be more cost competitive in the global space market. The H-2A rocket successfully lifted off from the Tanegashima Space Center in southwestern Japan, carrying the GOSAT-GW satellite as part of Tokyo's effort to mitigate climate change. The satellite was released into orbit about 16 minutes later. Mitsubishi Heavy Industries, which operates the rocket launch, and Japan Aerospace Exploration Agency, will hold a news conference later Sunday to give further details of the flight. Sunday's launch marked the 50th and final flight for the H-2A, which has served as Japan's mainstay rocket to carry satellites and probes into space with a near-perfect record since its 2001 debut. After its retirement, it will be fully replaced by the H3, which is already in operation, as Japan's new main flagship. The launch follows several days of delays because of malfunctioning of the rocket's electrical systems. The GOSAT-GW, or Global Observing SATellite for Greenhouse gases and Water cycle, is a third series in the mission to monitor carbon, methane and other greenhouse gasses in the atmosphere. It will start distributing data in about one year, officials said. The liquid-fuel H-2A rocket with two solid-fuel sub-rockets developed by Japan Aerospace Exploration Agency has so far had 49 flights with a 98% success record, with only one failure in 2003. Mitsubishi Heavy Industries has provided its launch operation since 2007. H-2A successfully carried into space Japan's moon lander SLIM last year, and a popular Hayabusa2 spacecraft in 2014 to reach a distant asteroid, contributing to the country's space programs. Japan sees a stable, commercially competitive space transport capability as key to its space program and national security, and has been developing two new flagship rockets as successors of the H-2A series — the larger H3 with Mitsubishi, and a much smaller Epsilon system with the aerospace unit of the heavy machinery maker IHI. It hopes to cater to diverse customer needs and improve its position in the growing satellite launch market. The H3, is designed to carry larger payloads than the H-2A at about half its launch cost to be globally competitive, though officials say more cost reduction efforts are needed to achieve better price competitiveness in the global market. The H3 has made four consecutive successful flights after a failed debut attempt in 2023, when the rocket had to be destroyed with its payload. Mari Yamaguchi, The Associated Press
CBC
7 hours ago
- CBC
Health minister confident deal will be reached to prevent mass resignations at St. Clare's
Newfoundland and Labrador's health minister said she wasn't fond of the approach, but she expects a deal is "imminent" with a team of doctors who threatened a mass resignation at St. Clare's Mercy Hospital in St. John's. Krista Lynn Howell told reporters Friday afternoon that her department has been working with the provincial health authority and the medical association to find a solution to the problems with internal medicine at the city's second-largest hospital. The five internists warned of an "impending crisis" following the loss of the medical residency program at the hospital — stripping away valuable coverage for 24/7 patient care. "I may disagree with the tactics that were deployed to get us to this point today," Howell said. "But nobody has thrown down and went home. So we do believe that we're in a place right now where a resolution is imminent and we're confident the plan will resolve this issue." Howell gave no particulars, instead deferring to Newfoundland and Labrador Health Services (NLHS) and the Newfoundland and Labrador Medical Association (NLMA). In a brief comment, Kyle Rees — a lawyer retained by the five doctors — said he's encouraged. "I know the parties are working on it, and that's a positive development. It's something that needs to be taken seriously, and it sounds like that's happening." Doctors threatened resignation before News of the resignation notice caused a frenzy on Friday, but it wasn't the first time the team of physicians has threatened to walk away. CBC Investigates has obtained a letter dated Jan. 1, 2024, in which the internal medicine team at St. Clare's wrote to the premier's office and threatened to withhold services within 20 days. They cited reasons such as "administrative burden, limited resources and an overwhelming patient load," as well as compensation "significantly lower" than the national average. "We understand that our decision to withdraw services may cause inconvenience and disruption to both N.L. Health Services and our patients," they wrote at the time. "However, we firmly believe that this step is necessary to draw attention to the urgent need for change." The letter did not result in a job action — which is prohibited under their collective agreement — but three of the five signatories to the letter no longer work at St. Clare's. Barry Petten, the Progressive Conservative health critic, said he wasn't surprised by the new resignation letter sent on Monday. He said he's had contact with internists from St. Clare's going back to the first resignation threat last year. Petten said he knows the doctors reached out to the last three health ministers — including Premier John Hogan. "And yet, no action," he said. "This is not a new thing. Eighteen months later, there's no action." Howell acknowledged the issue has been ongoing, but said talks have been happening for several months. She said a plan to address their concerns was well underway before they were told the residency program was coming to an end, creating a new problem to overcome. Residency program axed over lack of supervision, MUN says In a statement on Friday, Memorial University said it made the decision to cut the residency program "in the best interest of our residents' training and well-being." The statement said the university's medical school had concerns about "a lack of adequate support and appropriate supervision" for residents, leading to the entire program being terminated. Spokesperson Chad Pelley said some modifications were made as concerns were raised, but they weren't enough to satisfy national standards during an accreditation review last November. Formal notice was given in early 2025, outlining the issues that needed to be resolved. The internal medicine residency at St. Clare's will come to an end on July 1. Howell, meanwhile, said the residency program is important to the hospital, and she's hoping to see it restored in the future.
